###begin article-title 0
###xml 70 81 <span type="species:ncbi:11103">Hepatitis C</span>
Reliance of Host Cholesterol Metabolic Pathways for the Life Cycle of Hepatitis C Virus
###end article-title 0
###begin p 1
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 126 132 <span type="species:ncbi:9606">people</span>
###xml 227 230 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 430 433 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 521 524 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV), a single-stranded positive-sense RNA virus of the Flaviviridae family, infects more than 170 million people worldwide and is the leading cause of liver failure in the United States. A unique feature of HCV is that the viral life cycle depends on cholesterol metabolism in host cells. This review summarizes the cholesterol metabolic pathways that are required for the replication, secretion, and entry of HCV. The potential application of drugs that alter host cholesterol metabolism in treating HCV infection is also discussed.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b001">1</xref>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b002">2</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b003">3</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b004">4</xref>
###xml 831 832 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b005">5</xref>
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 133 136 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 296 299 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 477 480 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 621 624 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
###xml 878 881 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) exacts a heavy toll on public health. Approximately 3% of the world population is infected persistently with HCV [1]. According to the Centers for Disease Control and Prevention, 4.1 million Americans (1.6% of the United States population) are estimated to be infected by HCV, 3.2 million of whom become chronically infected [2]. These individuals account for most of the cases of liver failure in the United States [3]. Owing to its genomic variation, HCV variants are divided into six genotypes (genotypes 1-6), which differ from each other by 31% to 33% at the nucleotide level [4]. Genotype 1 HCV is the most prevalent viral variant found in the United States. This genotype is also less sensitive to the current interferon-based therapies, with only about 50% of patients responding to such treatment [5]. Thus, new therapeutic strategies to combat HCV infection are needed.
###end p 3
###begin p 4
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b006">6</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b007">7</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b008">8</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b009">9</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b010">10</xref>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 99 102 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV is a single-stranded positive-sense RNA virus of the Flaviviridae family [6]. The 9.6-kilobase HCV genome encodes a single polyprotein that is post-translationally processed into at least ten structural and nonstructural (NS) proteins [7]. The amino-terminal third of the polyprotein encodes the virion structural proteins: core, E1, and E2, which are followed by a small integral membrane protein p7 that functions as an ion channel [8]. The remainder of the genome encodes the nonstructural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B. Except for NS2, all of the other NS proteins are required for efficient viral RNA replication. These NS proteins (NS3-NS5B) form a viral replication complex on intracellular membrane vesicles, leading to a structure termed the membranous web [9,10].
###end p 4
###begin p 5
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b007">7</xref>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">neo,</italic>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b011">11</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b012">12</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b014">14</xref>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b015">15</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b015">15</xref>
###xml 52 55 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 127 130 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 177 180 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 221 224 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 494 499 <span type="species:ncbi:9606">human</span>
###xml 542 545 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 620 623 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 709 712 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 760 763 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 808 811 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 879 882 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 944 947 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1055 1066 <span type="species:ncbi:9598">chimpanzees</span>
###xml 1074 1078 <span type="species:ncbi:10090">mice</span>
###xml 1090 1095 <span type="species:ncbi:9606">human</span>
###xml 1250 1253 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
For reasons still unknown, most clinically isolated HCV is difficult to replicate in cultured cells [7]. Thus, cells harboring HCV subgenomic replicons are widely used to study HCV replication. These replicons consist of HCV RNA engineered to express a selectable marker gene, neo, in place of the structural protein-coding region. A heterologous viral internal ribosomal entry site is inserted after the neomycin resistance cassette to direct translation of viral NS proteins (NS3-NS5B). When human hepatoma Huh7 cells were transfected with HCV replicon RNA and selected with G418, a cell line was established in which HCV RNA was constantly replicated [11]. This system, although very effective in studying HCV replication, is not able to produce infectious HCV particles. Recently, a strain of genotype 2 HCV was shown to be capable of replicating in Huh7 cells and producing HCV particles that are infectious to cultured cells [12-14]. The HCV particles produced from cell culture (referred to as HCVcc) were able to establish long-term infections in chimpanzees and in mice containing human liver grafts [15]. Moreover, virus recovered from these animals was still infectious in cell culture [15]. For reasons still unknown, only this strain of HCV or its derivative can be cultured in Huh7 cells to generate infectious viral particles.
###end p 5
###begin p 6
###xml 51 52 51 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b001">1</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b016">16</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b017">17</xref>
###xml 452 460 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030108-g001">Figure 1</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b018">18</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b018">18</xref>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV infection is mainly restricted to hepatocytes [1], which play a vital role in mammalian cholesterol homeostasis. Like all mammalian cells, hepatocytes are able to acquire cholesterol through two pathways. Cholesterol can be synthesized from acetyl-CoA via the mevalonate pathway [16], which also generates several isoprenoids, including farnesyl and geranylgeranyl lipids that are covalently attached to the COOH-terminus of certain proteins [17] (Figure 1). Cells can also acquire low density lipoprotein (LDL)-associated cholesterol in serum through LDL receptor-mediated endocytosis [18]. The LDL receptor binds to LDL particles, which are internalized via the clathrin-dependent pathway of receptor-mediated endocytosis. Following endocytosis, the lipoprotein is degraded in lysosomes and cholesterol in LDL is released into the cells [18].
###end p 6
###begin title 7
###xml 42 45 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Requirement of the Mevalonate Pathway for HCV Replication
###end title 7
###begin p 8
###xml 242 245 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 423 426 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Cells are capable of synthesizing cholesterol through the mevalonate pathway. This pathway also produces geranylgeranyl lipid, which is attached to the COOH-terminus of FBL2. Geranylgeranylated FBL2 binds to NS5A, an interaction required for HCV RNA replication. Lovastatin, an inhibitor of HMG CoA reductase, blocks the entire mevalonate pathway. As a result, cells are depleted of geranylgeranyl lipid and replication of HCV is inhibited. PP, pyrophosphate.
###end p 8
###begin p 9
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b019">19</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b020">20</xref>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 210 216 <span type="species:ncbi:9606">humans</span>
###xml 296 302 <span type="species:ncbi:9606">humans</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 537 543 <span type="species:ncbi:9606">humans</span>
###xml 556 560 <span type="species:ncbi:10090">mice</span>
In mice, hepatocytes can also acquire a substantial amount of cholesterol through scavenger receptor class B type I (SR-BI)-mediated uptake of cholesterol from high density lipoprotein (HDL) particles [19]. In humans, hepatic cholesterol contributed by HDL is not as significant. This is because humans, but not mice, express cholesteryl ester transfer protein, which transfers cholesterol from HDL to LDL or its precursor, very low density lipoprotein (VLDL) [20]. As a result, the amount of HDL-associated cholesterol is much lower in humans compared to mice, in which HDL particles transport most of the plasma cholesterol.
###end p 9
###begin p 10
###xml 159 167 159 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030108-g002">Figure 2</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b021">21</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b022">22</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b023">23</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b024">24</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b025">25</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b026">26</xref>
###xml 1322 1324 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b027">27</xref>
Hepatocytes play a crucial role in regulating mammalian cholesterol metabolism by exporting cholesterol together with triglycerides through secretion of VLDL (Figure 2). The assembly of VLDL begins with synthesis of full length apolipoprotein B (apoB), a 540-kDa protein that confers structural integrity to VLDL [21]. Nascent apoB is then fused with lipid droplets that are rich in triglyceride and cholesteryl esters in the lumen of the endoplasmic reticulum (ER). While most cells contain cytosolic lipid droplets, hepatocytes, as well as other cells producing lipoprotein particles that contain apoB, have lipid droplets in the lumen of the ER [22]. Fusion between lipid droplets and apoB requires the activity of microsomal triglyceride transfer protein (MTP) [23]. Without MTP-mediated lipid transfer, the secretion of apoB is blocked and the protein is degraded in cells [24]. The importance of MTP in VLDL assembly is demonstrated by the observations that genetic defects in MTP severely reduce VLDL secretion [25,26]. The resulting VLDL particles are composed of a hydrophobic core of triglycerides and cholesteryl esters surrounded by a surface coat containing phospholipids, free cholesterol, and two predominant lipoproteins, apoB and apolipoprotein E (apoE). VLDL is secreted out of cells through exocytosis [27].
###end p 10
###begin title 11
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV Replicates on ER Membranes Involved in the Assembly of VLDL and Is Secreted Together with VLDL
###end title 11
###begin p 12
###xml 512 515 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 552 555 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 651 654 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The assembly of VLDL begins with the synthesis of apoB in the rough ER, resulting in the formation of a VLDL precursor that contains only a small amount of lipid. In the lumen of the ER, this precursor is fused with lipid droplets (enriched in triglyceride and cholesterol) to generate nascent VLDL. This reaction is mediated by MTP. The nascent VLDL particles, which contain both apoB and apoE, are secreted into plasma through exocytosis. The ER membranes involved in the assembly of VLDL are also enriched in HCV NS proteins and RNA. Replication of HCV on these membranes might allow the virus to attach to or become incorporated into VLDL so that HCV is secreted together with VLDL.
###end p 12
###begin p 13
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b028">28</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b029">29</xref>
###xml 430 432 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b018">18</xref>
###xml 636 638 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b030">30</xref>
###xml 730 732 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b018">18</xref>
Nascent VLDL particles released into plasma are not ligands for the LDL receptor [28]. These lipoprotein particles are substrates for lipoprotein lipase, which hydrolyzes the triglycerides in the core of the lipoprotein particles [29]. A large proportion (approximately70%) of the resulting particles, called intermediate density lipoprotein (IDL) particles, is efficiently removed from plasma by the LDL receptor on hepatocytes [18]. The remaining IDL particles in the circulation are converted to LDL particles by a reaction catalyzed by hepatic lipase, which further reduces the amount of triglycerides in the lipoprotein particles [30]. Once formed, LDL is taken up by the LDL receptor on hepatic as well as nonhepatic cells [18].
###end p 13
###begin title 14
###xml 41 44 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Requirement of the Mevalonate Pathway in HCV RNA Replication
###end title 14
###begin p 15
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b016">16</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b032">32</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b034">34</xref>
###xml 58 61 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 319 322 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The first clue that the mevalonate pathway is involved in HCV RNA replication was the finding that treatment of cultured cells with lovastatin, a cholesterol-lowering drug that inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in the entire mevalonate pathway [16], inhibited HCV RNA replication [31]. Similar results were subsequently obtained by others [32-34].
###end p 15
###begin p 16
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b032">32</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b017">17</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b017">17</xref>
###xml 51 54 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 162 165 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 591 594 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 669 672 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The product of the mevalonate pathway required for HCV RNA replication turns out to be a geranylgeranyl lipid, as shown by experiments in which the inhibition of HCV RNA replication by lovastatin was overcome by the addition of geranylgeraniol, but not farnesol or cholesterol [31,32]. Geranylgeranyl serves as a lipid substrate for protein geranylgeranylation, a post-translational modification that covalently attaches geranylgeranyl to various cellular proteins to facilitate their membrane association [17]. Thus, it appears that one or more geranylgeranylated proteins are required for HCV RNA replication. This notion is further supported by the observation that HCV replication could be blocked by an inhibitor of geranylgeranyl transferase I [31], an enzyme that transfers geranylgeranyl groups to cellular proteins [17].
###end p 16
###begin p 17
###xml 91 93 91 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AA</italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b035">35</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b035">35</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b035">35</xref>
###xml 852 860 852 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030108-g001">Figure 1</xref>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b036">36</xref>
###xml 12 15 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 298 301 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 687 690 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 826 829 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 896 899 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1143 1146 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1238 1241 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1364 1367 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Inasmuch as HCV does not encode a viral protein that contains the signature COOH-terminal CAAX motif (i.e., cysteine-X-X-leucine or isoleucine, in which X is an aliphatic amino acid) that specifies geranylgeranylation, it was hypothesized that a geranylgeranylated host protein may be required for HCV RNA replication. In this regard, a 50-kDa geranylgeranylated host protein was found to co-immunoprecipitate with the viral protein NS5A [35]. With the knowledge of the molecular weight of the protein and the sequence motif that specifies geranylgeranylation, this protein was identified as FBL2 by a bioinformatics approach [35]. Geranylgeranylation of FBL2 appears to be critical for HCV replication because the association between FBL2 and NS5A depends on geranylgeranylation of FBL2, and this interaction is required for HCV RNA replication [35] (Figure 1). The exact role played by FBL2 in HCV RNA replication remains unclear because the physiological function of FBL2 is not known. FBL2 contains an F-box, a domain known to be involved in protein ubiquitination [36]. Thus, it is possible that protein ubiquitination may play a role in HCV RNA replication. It should be noted that all of the aforementioned studies used genotype 1 HCV replicons. It is not known whether geranylgeranylation of host proteins is required for replication of other genotypes of HCV.
###end p 17
###begin p 18
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 475 477 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b037">37</xref>
###xml 548 550 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b038">38</xref>
###xml 571 573 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b039">39</xref>
###xml 58 61 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 163 166 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 267 270 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 504 507 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 756 759 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Unlike geranylgeranyl, the requirement of cholesterol for HCV RNA replication is still under debate. The observation that addition of cholesterol failed to rescue HCV RNA replication in the presence of lovastatin suggests that cholesterol is not directly involved in HCV RNA replication [31]. However, differing results were obtained when cells were depleted of cholesterol by treatment with methyl-beta-cyclodextrin, which directly extracts cholesterol from cell membranes [37]. Under these conditions, HCV RNA replication is either not affected [38] or reduced by 50% [39]. The inconsistency in these results could arise from a secondary effect of general cellular toxicity that occurs when cells are depleted of cholesterol, or from a difference in the HCV genotype used in these studies.
###end p 18
###begin title 19
###xml 33 36 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Requirement for VLDL Assembly in HCV Secretion
###end title 19
###begin p 20
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b009">9</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b040">40</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b041">41</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b041">41</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b041">41</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b042">42</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b044">44</xref>
###xml 934 942 934 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030108-g002">Figure 2</xref>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b045">45</xref>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b041">41</xref>
###xml 38 41 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 131 134 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 267 270 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 322 325 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 377 380 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 606 609 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 690 693 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 812 815 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 919 922 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1006 1009 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1101 1104 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Like all positive-strand RNA viruses, HCV RNA replication occurs in association with cytoplasmic membrane vesicles. In the case of HCV, these structures (membranous webs) have been visualized in cultured human hepatoma Huh7 cells that harbor a subgenomic replicon of HCV [9,40]. Recently, membrane vesicles containing the HCV replication complex from Huh7 cells that harbor an HCV replicon were isolated [41]. Proteomic analysis revealed that these vesicles are enriched in apoB, apoE, and MTP, proteins known to be required for the assembly of VLDL [41]. Interestingly, VLDL synthesis is not required for HCV RNA replication [41]. This result is consistent with the previous findings that HCV RNA can replicate in HeLa and HEK-293 cells [42-44], which do not produce VLDL. The reason for co-localization of the HCV replication and VLDL assembly appears to lie in a requirement for co-assembly or secretion of VLDL and HCV particles (Figure 2). Thus, When Huh7 cells that constitutively produce infectious HCV [45] were treated with an MTP inhibitor or siRNA targeting apoB, the secretion of VLDL and HCV were both inhibited [41].
###end p 20
###begin p 21
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b046">46</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b048">48</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b046">46</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b047">47</xref>
###xml 768 770 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b049">49</xref>
###xml 1587 1589 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b013">13</xref>
###xml 1812 1814 1812 1814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b050">50</xref>
###xml 1815 1817 1815 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b051">51</xref>
###xml 40 43 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 120 123 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 170 173 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 261 264 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 446 449 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 489 492 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
###xml 539 542 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 701 704 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 717 720 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 921 924 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1094 1097 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1169 1172 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1271 1274 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1673 1676 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1853 1856 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Although VLDL secretion is required for HCV production in cultured cells, this requirement has not been demonstrated in HCV-infected patients. However, it was shown that HCV particles circulating in serum are in complex with VLDL [46-48]. Thus, it appears that HCV particles are attached to or incorporated into VLDL during the assembly of the lipoprotein particles and secreted together with VLDL. Although the nature of the association between HCV and VLDL remains unclear, studies with HCV isolated from infected patients suggests that HCV may reside in the lipid-rich core of VLDL, since delipidation of lipoprotein particles that contain apoB is required to observe the capsid-like structures of HCV [46,47]. If HCV indeed hides in the core of VLDL as suggested [49], it makes the virus unique in that the entire virion is not exposed to serum during circulation. If this model is correct, it will also predict that HCV has to escape from VLDL-derived lipoprotein particles during viral entry so that the structural protein E2 can interact with its cellular receptors, a step required for HCV RNA to enter cytosol (see below). Exactly what triggers the release of HCV from the lipoprotein particles is not known. If LDL receptor-mediated endocytosis is required for HCV entry (see below), the virus is likely to escape VLDL-derived particles in endocytic vesicles after the lipoprotein particles are disassembled during endocytosis. This scenario does not necessarily contradict the observation that entry of HCVcc was inhibited by antibodies targeting viral structural protein E2 [13], since these antibodies might also be included in endocytic vesicles that contain HCV. It was reported previously that immunoglobin G is able to enter clathrin-coated pits nonspecifically through fluid-phase endocytosis [50,51]. Thus, these antibodies may block HCV entry by binding to the viral structural protein after the virus is released from the lipoprotein particles in endocytic vesicles.
###end p 21
###begin p 22
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b052">52</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b053">53</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b054">54</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b055">55</xref>
###xml 21 24 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 131 134 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 186 189 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 446 449 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 475 490 <span type="species:ncbi:10090">transgenic mice</span>
###xml 502 505 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
###xml 668 671 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 711 714 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 802 805 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The observation that HCV replicates on membrane vesicles involved in the assembly of VLDL might also help to explain the effect of HCV infection on hepatic release of VLDL. Infection by HCV, particularly the genotype 3 variant, leads to a reduced rate of VLDL secretion [52,53]. The reduction in VLDL secretion could arise from inhibition of MTP by viral proteins. It has been reported that mRNA levels of MTP are reduced in Huh7 cells harboring HCV replicons [54], and that transgenic mice expressing HCV core protein in livers have reduced MTP activity [55]. However, the reduction in MTP activity has not been demonstrated in cells or patients that are infected by HCV. The role of reduced VLDL secretion in HCV infection is currently unknown. It is possible that by delaying the secretion of VLDL, HCV might have enough time to replicate and assemble into VLDL.
###end p 22
###begin p 23
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b056">56</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b057">57</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b058">58</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b058">58</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b059">59</xref>
###xml 187 190 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 251 254 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 296 299 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 392 395 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 420 423 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 553 556 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 653 656 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Besides liver, intestine is the only other tissue that produces apoB-containing lipoprotein particles. These particles, called chylomicrons, contain a shorter form of apoB [56]. Although HCV infection in intestinal cells was reported in a fraction of HCV-infected patients [57,58], the amount of HCV detected in intestine was much lower than that in liver [58]. However, in patients that had HCV infection in intestine, HCV particles circulating in serum were in complex with chylomicrons [59]. Thus, it appears that intestinal cells are able to export HCV, but they might not contain cellular factors that support efficient entry and/or replication of HCV.
###end p 23
###begin title 24
###xml 41 44 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Requirement of Lipoprotein Receptors for HCV Entry
###end title 24
###begin p 25
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b060">60</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b061">61</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b013">13</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b062">62</xref>
###xml 459 461 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b038">38</xref>
###xml 552 554 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b063">63</xref>
###xml 837 839 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b013">13</xref>
###xml 840 842 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b063">63</xref>
###xml 970 972 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b064">64</xref>
###xml 1072 1074 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b065">65</xref>
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 84 87 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 135 138 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 448 451 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 623 626 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 893 896 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 937 940 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1067 1070 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1113 1116 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1214 1217 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV enters cells through multiple cellular receptors. CD81, which directly binds to HCV structural protein E2 [60,61], is required for HCV to enter host cells [13,62]. Interestingly, the amount of CD81 expressed on the cell surface is affected by cellular cholesterol content. When cells were depleted of cholesterol by treatment with methyl-beta-cyclodextrin, the amount of CD81 located on plasma membrane was reduced, resulting in a reduction in HCV entry [38]. Recently, claudin-1 was identified as a receptor functioning at a step later than CD81 [63]. Both CD81 and claudin-1 have been demonstrated to be required for HCV entry by experiments showing that viral entry was blocked in cells that do not express either one of these proteins, and that reintroduction of the protein into the cells specifically restores the viral entry [13,63]. These receptors appear to act at later steps of HCV entry, because CD81 is not required for HCV to bind to the cell surface [64] and is not known to initiate the clathrin-mediated endocytosis that is required for entry of HCV [65]. Considering the association between HCV and VLDL-derived lipoprotein particles, lipoprotein receptors might function at earlier steps in HCV entry.
###end p 25
###begin p 26
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b066">66</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b067">67</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b047">47</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b068">68</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b070">70</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b071">71</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b071">71</xref>
###xml 197 200 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 270 273 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 426 429 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 453 456 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 476 479 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 541 544 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 731 734 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 921 924 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The LDL receptor, which plays a predominant role in acquiring VLDL-derived lipoprotein particles through clathrin-mediated endocytosis in hepatic cells [66,67], has been reported to be involved in HCV entry. These studies demonstrated that cellular binding or uptake of HCV particles isolated from infected patients correlated with LDL receptor activity on the cell surface [47,68-70]. In contrast to the results with genuine HCV isolated from serum of HCV-infected patients, HCV pseudo particles (HCVpp), which were assembled by displaying HCV structural proteins E1and E2 onto retroviral core particles, did not require the LDL receptor for their entry [71]. These results do not argue against an LDL receptor-mediated uptake of HCV since HCVpp were produced in HEK-293 cells that do not produce VLDL [71]. These results also suggest that virus-associated lipoproteins are required for LDL receptor-mediated binding of HCV.
###end p 26
###begin p 27
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b007">7</xref>
###xml 46 49 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 114 117 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 268 271 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 555 558 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Nevertheless, the role of the LDL receptor in HCV entry is still uncertain, because cellular binding or uptake of HCV in all of the aforementioned studies did not result in viral infection. This outcome could be explained by the difficulty of most clinically isolated HCV to replicate in cultured cells [7]. However, the possibility that LDL receptor-mediated viral entry does not lead to viral infection cannot be ruled out. More studies using HCVcc that effectively infect cultured cells are needed to demonstrate the requirement of the LDL receptor in HCV entry.
###end p 27
###begin p 28
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b072">72</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b072">72</xref>
###xml 351 354 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 408 411 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 458 461 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 475 481 <span type="species:ncbi:9606">people</span>
Mutations disrupting the function of the LDL receptor produce autosomal dominant familial hypercholesterolemia, which affects 0.2% of the world population [72]. Affected individuals have elevated plasma levels of LDL cholesterol, which causes premature coronary atherosclerosis [72]. Mutations in LDL receptors might protect affected individuals from HCV infection, if the LDL receptor is indeed involved in HCV entry. An analysis comparing the frequency of HCV infection in people expressing normal LDL receptor versus those affected by familial hypercholesterolemia will be needed to address the question.
###end p 28
###begin p 29
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b073">73</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b074">74</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b075">75</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b038">38</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b076">76</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b077">77</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b078">78</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b079">79</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b082">82</xref>
###xml 51 54 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 149 152 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 368 371 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 479 482 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 562 565 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Another lipoprotein receptor that is implicated in HCV entry is SR-BI, which binds to HDL [73] and oxidized LDL [74,75]. The involvement of SR-BI in HCV entry is indicated by the observations that entry of HCVcc to cells was blocked by antibodies directed against SR-BI [38,76] and inhibited by excessive amounts of oxidized LDL [77]. However, it is not known whether HCV entry is blocked in cells that do not express SR-BI. Unlike with the LDL receptor, the interaction between HCV and SR-BI may not depend on lipoproteins associated with the virus because the HCV structural protein E2 directly binds to SR-BI [78]. This notion is further supported by observations that entry of HCVpp, which does not associate with VLDL, required SR-BI [79-82].
###end p 29
###begin title 30
###xml 86 89 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Potential Application of Drugs That Target Cholesterol Metabolic Pathways in Treating HCV Infection
###end title 30
###begin p 31
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b083">83</xref>
###xml 30 33 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 283 286 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 372 375 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 588 591 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
A major obstacle in combating HCV infection is that the fidelity of the viral replication machinery is notoriously low, thus enabling the virus to quickly develop mutations that resist compounds targeting viral enzymes [83]. Therefore, drugs targeting the host proteins required for HCV infection may be more effective in combating the viral infection. A unique aspect of HCV that has not been observed in other viruses is that the entire viral life cycle is associated with cholesterol metabolism in host cells. Thus, drugs that target cholesterol metabolism might be useful in treating HCV infection.
###end p 31
###begin p 32
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b034">34</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b031">31</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b032">32</xref>
###xml 106 109 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 454 457 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Treatment of cells with statins, the widely used cholesterol-lowering drugs, has been reported to inhibit HCV RNA replication [31-34] by depletion of geranylgeranyl lipids [31,32]. However, the doses of statins currently used to treat hypercholesterolemia by inhibiting cholesterol synthesis, thereby stimulating expression of the LDL receptor in the liver, are not high enough to inhibit the synthesis of geranylgeranyl lipid. Applying statins to treat HCV will require much higher doses and would likely cause toxicity in the liver and other organs.
###end p 32
###begin p 33
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b041">41</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b084">84</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b085">85</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b086">86</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b085">85</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b086">86</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030108-b085">85</xref>
###xml 155 158 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 977 980 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Another class of drugs designed for treating hypercholesterolemia blocks the assembly and secretion of VLDL. These drugs may also be effective in treating HCV infection because they inhibit production of HCV particles from infected cells [41]. In this regard, antisense RNA drugs targeting apoB [84] and several MTP inhibitors [85,86] have already been tested in clinical trails because of their ability to block VLDL secretion, thereby lowering the plasma levels of VLDL triglycerides and LDL cholesterol. Long-term treatment with MTP inhibitors led to the toxic accumulation of fat in livers [85,86], thus hampering the approval of these drugs for the treatment hypercholesterolemia on a long-term basis. However, short-term treatment (up to several weeks) reduced the plasma level of VLDL with only minor adverse effects, which disappeared after drug removal [85]. It will be interesting to examine whether short-term treatment with MTP inhibitors is beneficial in treating HCV infection.
###end p 33
###begin title 34
Supporting Information
###end title 34
###begin title 35
Accession Numbers
###end title 35
###begin p 36
###xml 75 80 <span type="species:ncbi:9606">human</span>
The National Center for Biotechnology Information () accession numbers for human apoB, apoE, CD81, claudin-1, FBL2, LDL receptor, MTP, and SR-BI are NP_000375, NP_000032, NP_004347, NP_066924, NP_036289, NP_000518, NP_000244, and NP_005496, respectively. 
###end p 36
###begin p 37
I thank Helen Hobbs, Jay Horton, and Joseph Goldstein for their critical comments to the manuscript.
###end p 37
###begin title 38
Abbreviations
###end title 38
###begin p 39
apolipoprotein
###end p 39
###begin p 40
endoplasmic reticulum
###end p 40
###begin p 41
###xml 0 17 <span type="species:ncbi:11103">hepatitis C virus</span>
hepatitis C virus
###end p 41
###begin p 42
high density lipoprotein
###end p 42
###begin p 43
3-hydroxy-3-methylglutaryl coenzyme A
###end p 43
###begin p 44
intermediate density lipoprotein
###end p 44
###begin p 45
low density lipoprotein
###end p 45
###begin p 46
microsomal triglyceride transfer protein
###end p 46
###begin p 47
nonstructural
###end p 47
###begin p 48
scavenger receptor class B type I
###end p 48
###begin p 49
very low density lipoprotein
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
###xml 13 30 <span type="species:ncbi:11103">hepatitis C virus</span>
Unscrambling hepatitis C virus-host interactions
###end article-title 51
###begin article-title 52
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
Hepatitis C and liver transplantation
###end article-title 52
###begin article-title 53
###xml 25 42 <span type="species:ncbi:11103">hepatitis C virus</span>
Clinical significance of hepatitis C virus genotypes
###end article-title 53
###begin article-title 54
###xml 64 75 <span type="species:ncbi:11103">hepatitis C</span>
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
###end article-title 54
###begin article-title 55
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
From structure to function: New insights into hepatitis C virus RNA replication
###end article-title 55
###begin article-title 56
###xml 12 29 <span type="species:ncbi:11103">hepatitis C virus</span>
Unravelling hepatitis C virus replication from genome to function
###end article-title 56
###begin article-title 57
###xml 4 21 <span type="species:ncbi:11103">hepatitis C virus</span>
The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives
###end article-title 57
###begin article-title 58
###xml 22 39 <span type="species:ncbi:11103">hepatitis C virus</span>
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons
###end article-title 58
###begin article-title 59
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex
###end article-title 59
###begin article-title 60
###xml 26 43 <span type="species:ncbi:11103">hepatitis C virus</span>
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
###end article-title 60
###begin article-title 61
###xml 25 42 <span type="species:ncbi:11103">hepatitis C virus</span>
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
###end article-title 61
###begin article-title 62
###xml 24 41 <span type="species:ncbi:11103">hepatitis C virus</span>
Complete replication of hepatitis C virus in cell culture
###end article-title 62
###begin article-title 63
###xml 7 24 <span type="species:ncbi:11103">hepatitis C virus</span>
Robust hepatitis C virus infection in vitro
###end article-title 63
###begin article-title 64
###xml 19 36 <span type="species:ncbi:11103">hepatitis C virus</span>
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
###end article-title 64
###begin article-title 65
Regulation of the mevalonate pathway
###end article-title 65
###begin article-title 66
Protein prenylation: Molecular mechanisms and functional consequences
###end article-title 66
###begin article-title 67
Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system
###end article-title 67
###begin article-title 68
Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein receptor SR-BI
###end article-title 68
###begin article-title 69
A review of CETP and its relation to atherosclerosis
###end article-title 69
###begin article-title 70
Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
###end article-title 70
###begin article-title 71
Mechanisms of lipid-body formation
###end article-title 71
###begin article-title 72
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
###end article-title 72
###begin article-title 73
Hepatic regulation of apolipoprotein B
###end article-title 73
###begin article-title 74
Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia
###end article-title 74
###begin article-title 75
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Knockout of the abetalipoproteinemia gene in mice: Reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes
###end article-title 75
###begin article-title 76
Synthesis and function of hepatic very-low-density lipoprotein
###end article-title 76
###begin article-title 77
###xml 99 104 <span type="species:ncbi:9606">human</span>
Mechanisms of inhibition by apolipoprotein C of apolipoprotein E- dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
###end article-title 77
###begin article-title 78
Lipoprotein lipase: Structure, function, regulation, and role in disease
###end article-title 78
###begin article-title 79
Hepatic lipase: Structure/function relationship, synthesis, and regulation
###end article-title 79
###begin article-title 80
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation
###end article-title 80
###begin article-title 81
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
###end article-title 81
###begin article-title 82
###xml 70 87 <span type="species:ncbi:11103">hepatitis C virus</span>
A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication
###end article-title 82
###begin article-title 83
###xml 15 18 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Different anti-HCV profiles of statins and their potential for combination therapy with interferon
###end article-title 83
###begin article-title 84
###xml 77 94 <span type="species:ncbi:11103">hepatitis C virus</span>
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication
###end article-title 84
###begin article-title 85
The SCF ubiquitin ligase: Insights into a molecular machine
###end article-title 85
###begin article-title 86
Cellular cholesterol efflux mediated by cyclodextrins
###end article-title 86
###begin article-title 87
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I
###end article-title 87
###begin article-title 88
###xml 24 41 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts
###end article-title 88
###begin article-title 89
###xml 111 128 <span type="species:ncbi:11103">hepatitis C virus</span>
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes
###end article-title 89
###begin article-title 90
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 32 37 <span type="species:ncbi:9606">human</span>
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
###end article-title 90
###begin article-title 91
###xml 72 89 <span type="species:ncbi:11103">hepatitis C virus</span>
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon
###end article-title 91
###begin article-title 92
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line
###end article-title 92
###begin article-title 93
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells
###end article-title 93
###begin article-title 94
###xml 32 49 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 51 54 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 68 71 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells
###end article-title 94
###begin article-title 95
###xml 17 28 <span type="species:ncbi:11103">hepatitis C</span>
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins
###end article-title 95
###begin article-title 96
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles
###end article-title 96
###begin article-title 97
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
###end article-title 97
###begin article-title 98
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus particles and lipoprotein metabolism
###end article-title 98
###begin article-title 99
###xml 21 26 <span type="species:ncbi:9606">human</span>
Coated vesicles from human placenta carry ferritin, transferrin, and immunoglobulin G
###end article-title 99
###begin article-title 100
IgG transport across trophoblast-derived BeWo cells: A model system to study IgG transport in the placenta
###end article-title 100
###begin article-title 101
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 84 87 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a
###end article-title 101
###begin article-title 102
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 97 108 <span type="species:ncbi:11103">hepatitis C</span>
Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C
###end article-title 102
###begin article-title 103
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion
###end article-title 103
###begin article-title 104
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis
###end article-title 104
###begin article-title 105
Mobilisation of triacylglycerol stores
###end article-title 105
###begin article-title 106
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo
###end article-title 106
###begin article-title 107
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 67 78 <span type="species:ncbi:11103">hepatitis C</span>
Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C
###end article-title 107
###begin article-title 108
###xml 28 45 <span type="species:ncbi:11103">hepatitis C virus</span>
Preferential association of hepatitis C virus with apolipoprotein B48-containing lipoproteins
###end article-title 108
###begin article-title 109
###xml 26 43 <span type="species:ncbi:11103">hepatitis C virus</span>
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
###end article-title 109
###begin article-title 110
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
Binding of hepatitis C virus to CD81
###end article-title 110
###begin article-title 111
###xml 87 98 <span type="species:ncbi:11103">hepatitis C</span>
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C Virus into host cells
###end article-title 111
###begin article-title 112
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
###end article-title 112
###begin article-title 113
###xml 32 49 <span type="species:ncbi:11103">hepatitis C virus</span>
CD81 is an entry coreceptor for hepatitis C virus
###end article-title 113
###begin article-title 114
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus entry depends on clathrin-mediated endocytosis
###end article-title 114
###begin article-title 115
The low-density lipoprotein pathway and its relation to atherosclerosis
###end article-title 115
###begin article-title 116
###xml 127 133 <span type="species:ncbi:9606">humans</span>
Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans
###end article-title 116
###begin article-title 117
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor
###end article-title 117
###begin article-title 118
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 39 42 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 48 51 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor
###end article-title 118
###begin article-title 119
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 99 116 <span type="species:ncbi:11103">hepatitis C virus</span>
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus
###end article-title 119
###begin article-title 120
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
###end article-title 120
###begin article-title 121
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
###end article-title 121
###begin article-title 122
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
###end article-title 122
###begin article-title 123
CD36 is a receptor for oxidized low density lipoprotein
###end article-title 123
###begin article-title 124
Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein
###end article-title 124
###begin article-title 125
###xml 57 74 <span type="species:ncbi:11103">hepatitis C virus</span>
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity
###end article-title 125
###begin article-title 126
###xml 42 59 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
###end article-title 126
###begin article-title 127
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 82 99 <span type="species:ncbi:11103">hepatitis C virus</span>
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
###end article-title 127
###begin article-title 128
###xml 37 54 <span type="species:ncbi:11103">hepatitis C virus</span>
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
###end article-title 128
###begin article-title 129
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
###end article-title 129
###begin article-title 130
###xml 51 62 <span type="species:ncbi:11103">hepatitis C</span>
An interplay between hypervariable region 1 of the hepatitis C Virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies
###end article-title 130
###begin article-title 131
###xml 96 113 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
###end article-title 131
###begin article-title 132
###xml 57 68 <span type="species:ncbi:11103">hepatitis C</span>
Challenges and successes in developing new therapies for hepatitis C
###end article-title 132
###begin article-title 133
Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia
###end article-title 133
###begin article-title 134
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
###end article-title 134
###begin article-title 135
###xml 108 114 <span type="species:ncbi:9606">humans</span>
CP-346086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
###end article-title 135
###begin p 136
###xml 150 175 150 175 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jin.ye@utsouthwestern.edu</email>
Jin Ye is with the Department of Molecular Genetics, University of Texas Southwestern Medical Center. Dallas, Texas, United States of America. Email: jin.ye@utsouthwestern.edu
###end p 136
###begin p 137
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. JY wrote the article.
###end p 137
###begin p 138
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. JY is supported by research grants from the National Institutes of Health (HL-20948).
###end p 138
###begin p 139
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The author has declared that no competing interests exist.
###end p 139

